Geron Corp. buy klostergang
Start price
26.06.15
/
50%
€3.58
Target price
07.12.15
€4.50
Performance (%)
29.46%
End price
07.12.15
€4.63
Summary
This prediction ended on 07.12.15 with a price of €4.63. The BUY prediction by klostergang finished with a performance of 29.46%. klostergang has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Geron Corp. | -6.622% | -6.622% | -30.300% | -71.384% |
| iShares Core DAX® | -2.195% | 0.670% | 0.546% | 51.111% |
| iShares Nasdaq 100 | -2.629% | 2.992% | 34.108% | 91.988% |
| iShares Nikkei 225® | -2.021% | 3.141% | 53.424% | 65.852% |
| iShares S&P 500 | -1.670% | 2.405% | 23.220% | 66.636% |
Comments by klostergang for this prediction
In the thread Geron Corp. diskutieren
Mit JNJ-Partnerschaft und Orphan Drug der FDA gegen Krebs :
Geron Corp is a clinical stage biopharmaceutical company engaged in the discovery and development of therapeutic products for oncology such as telomerase inhibitor, imetelstat and in hematologic myeloid malignancies, among others.
(Vom Mitglied beendet)


